These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 30959553

  • 1. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib.
    Bort A, Sánchez BG, Mateos-Gómez PA, Vara-Ciruelos D, Rodríguez-Henche N, Díaz-Laviada I.
    Mol Oncol; 2019 May; 13(5):1311-1331. PubMed ID: 30959553
    [Abstract] [Full Text] [Related]

  • 2. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S, van der Helm D, Gray PC, Chen L, Klima I, Grosjean J, Burgmans MC, Farina-Sarasqueta A, Snaar-Jagalska EB, Stroka DM, Terracciano L, van Hoek B, Schaapherder AF, Osanto S, Thalmann GN, Verspaget HW, Coenraad MJ, Kruithof-de Julio M.
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [Abstract] [Full Text] [Related]

  • 3. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
    Huang M, Chen C, Geng J, Han D, Wang T, Xie T, Wang L, Wang Y, Wang C, Lei Z, Chu X.
    Cancer Lett; 2017 Jul 10; 398():12-21. PubMed ID: 28377178
    [Abstract] [Full Text] [Related]

  • 4. Dysregulated lipid metabolism in hepatocellular carcinoma cancer stem cells.
    Bort A, Sánchez BG, de Miguel I, Mateos-Gómez PA, Diaz-Laviada I.
    Mol Biol Rep; 2020 Apr 10; 47(4):2635-2647. PubMed ID: 32125560
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
    Wang M, Wang Z, Zhi X, Ding W, Xiong J, Tao T, Yang Y, Zhang H, Zi X, Zhou W, Huang G.
    Biomed Pharmacother; 2020 Sep 10; 129():110315. PubMed ID: 32554246
    [Abstract] [Full Text] [Related]

  • 8. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Zhai B, Zhang X, Sun B, Cao L, Zhao L, Li J, Ge N, Chen L, Qian H, Yin Z.
    Tumour Biol; 2016 Jun 10; 37(6):8047-55. PubMed ID: 26711788
    [Abstract] [Full Text] [Related]

  • 9. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 10. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
    Leung HW, Leung CON, Lau EY, Chung KPS, Mok EH, Lei MML, Leung RWH, Tong M, Keng VW, Ma C, Zhao Q, Ng IOL, Ma S, Lee TK.
    Cancer Res; 2021 Jun 15; 81(12):3229-3240. PubMed ID: 33903122
    [Abstract] [Full Text] [Related]

  • 11. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
    Huang WC, Tung SL, Chen YL, Chen PM, Chu PY.
    BMC Cancer; 2018 May 30; 18(1):609. PubMed ID: 29848298
    [Abstract] [Full Text] [Related]

  • 12. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC, Su YT, Chi CC, Kuo YC, Lee KF, Wu YC, Lan PC, Yang MH, Chang TS, Huang YH.
    J Exp Clin Cancer Res; 2019 Nov 26; 38(1):474. PubMed ID: 31771617
    [Abstract] [Full Text] [Related]

  • 13. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
    Song Y, Pan G, Chen L, Ma S, Zeng T, Man Chan TH, Li L, Lian Q, Chow R, Cai X, Li Y, Li Y, Liu M, Li Y, Zhu Y, Wong N, Yuan YF, Pei D, Guan XY.
    Gastroenterology; 2015 Oct 26; 149(4):1068-81.e5. PubMed ID: 26099525
    [Abstract] [Full Text] [Related]

  • 14. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, Jiang H, Liu J, Liu L.
    Hepatology; 2013 May 26; 57(5):1847-57. PubMed ID: 23299930
    [Abstract] [Full Text] [Related]

  • 15. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q, Zheng B, Meng S, Xu Y, Guo J, Chen LJ, Xiao J, Zhang W, Tan ZR, Tang J, Chen L, Chen Y.
    Biomed Pharmacother; 2019 Jun 26; 114():108864. PubMed ID: 30981107
    [Abstract] [Full Text] [Related]

  • 16. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX, Qi Y, Zhang J, Liu Y, Xu WH, Xu J, Hu HG, Wu QY, Wang Y, Zhang JP.
    Oncotarget; 2016 Nov 29; 7(48):79544-79556. PubMed ID: 27783993
    [Abstract] [Full Text] [Related]

  • 17. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
    Li M, Zhang L, Ge C, Chen L, Fang T, Li H, Tian H, Liu J, Chen T, Jiang G, Xie H, Cui Y, Yao M, Li J.
    Oncotarget; 2015 Sep 22; 6(28):25149-60. PubMed ID: 26327240
    [Abstract] [Full Text] [Related]

  • 18. TFAM depletion overcomes hepatocellular carcinoma resistance to doxorubicin and sorafenib through AMPK activation and mitochondrial dysfunction.
    Zhu Y, Xu J, Hu W, Wang F, Zhou Y, Xu W, Gong W, Shao L.
    Gene; 2020 Aug 30; 753():144807. PubMed ID: 32461017
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y, Huang J, Ma L, Shan J, Shen J, Yang Z, Liu L, Luo Y, Yao C, Qian C.
    Cancer Lett; 2016 Feb 28; 371(2):171-81. PubMed ID: 26655273
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.